Literature DB >> 19561096

Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression.

Toshio Yoshizawa1, Deepa Hammaker, David L Boyle, Maripat Corr, Richard Flavell, Roger Davis, Georg Schett, Gary S Firestein.   

Abstract

Development of p38alpha inhibitors for rheumatoid arthritis has been hindered by toxicity and limited efficacy. Therefore, we evaluated whether MKK6, an upstream kinase that regulates multiple p38 isoforms, might be an alternative therapeutic target in inflammatory arthritis. Wild-type (WT), MKK6(-/-), and MKK3(-/-) mice were administered K/BxN serum to induce arthritis. Articular expression of activated kinases and cytokines was determined by Western blot, qPCR, ELISA, and multiplex analysis. Immunoprecipitation and confocal microscopy experiments were performed to determine the subcellular location of MKK6, P-p38, and MAPKAPK2 (MK2). Arthritis scores were significantly lower in MKK6(-/-) mice compared with WT mice. Joint destruction and osteoclast differentiation were lower in MKK6(-/-), as were articular IL-6 and matrix metalloproteinase-3 expression. Phospho-p38 levels were modestly decreased in the joints of arthritic MKK6(-/-) mice compared with WT but were significantly higher than MKK3(-/-) mice. P-MK2 was low in MKK6(-/-) and MKK3(-/-) mice. Uncoupled p38 and MK2 activation was also observed in cultured, MKK6(-/-) FLS and confirmed using kinase assays. Immunoprecipitation assays and confocal microscopy showed that P-p38 and MK2 colocalized in activated WT but not MKK6(-/-) FLS. Distinct patterns of cytokine production were observed in MKK6(-/-) and MKK3(-/-) cells. MKK6 deficiency suppresses inflammatory arthritis and joint destruction, suggesting it might be a therapeutic target for inflammation. Although MKK3 and MKK6 activate the p38 pathway, they regulate distinct subsets of proinflammatory cytokines. MKK6 appears mainly to facilitate p38 and MK2 colocalization in the nucleus rather than to phosphorylate p38.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561096      PMCID: PMC2744479          DOI: 10.4049/jimmunol.0900483

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

Review 1.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.

Authors:  Sanjay Kumar; Jeffrey Boehm; John C Lee
Journal:  Nat Rev Drug Discov       Date:  2003-09       Impact factor: 84.694

2.  Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

Authors:  A M Badger; D E Griswold; R Kapadia; S Blake; B A Swift; S J Hoffman; G B Stroup; E Webb; D J Rieman; M Gowen; J C Boehm; J L Adams; J C Lee
Journal:  Arthritis Rheum       Date:  2000-01

3.  MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels.

Authors:  Armin Neininger; Dimitris Kontoyiannis; Alexey Kotlyarov; Reinhard Winzen; Rolf Eckert; Hans-Dieter Volk; Helmut Holtmann; George Kollias; Matthias Gaestel
Journal:  J Biol Chem       Date:  2001-12-06       Impact factor: 5.157

4.  MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis.

Authors:  A Kotlyarov; A Neininger; C Schubert; R Eckert; C Birchmeier; H D Volk; M Gaestel
Journal:  Nat Cell Biol       Date:  1999-06       Impact factor: 28.824

5.  Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis.

Authors:  G Schett; M Tohidast-Akrad; J S Smolen; B J Schmid; C W Steiner; P Bitzan; P Zenz; K Redlich; Q Xu; G Steiner
Journal:  Arthritis Rheum       Date:  2000-11

6.  Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export.

Authors:  Wuyi Meng; Lora L Swenson; Matthew J Fitzgibbon; Koto Hayakawa; Ernst Ter Haar; Anne E Behrens; John R Fulghum; Judith A Lippke
Journal:  J Biol Chem       Date:  2002-08-08       Impact factor: 5.157

7.  Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.

Authors:  Stanley B Cohen; Tien-Tsai Cheng; Vishala Chindalore; Nemanja Damjanov; Ruben Burgos-Vargas; Patricia Delora; Kathleen Zimany; Helen Travers; John P Caulfield
Journal:  Arthritis Rheum       Date:  2009-02

8.  Mechanism of p38 MAP kinase activation in vivo.

Authors:  Deborah Brancho; Nobuyuki Tanaka; Anja Jaeschke; Juan-Jose Ventura; Nyaya Kelkar; Yoshinori Tanaka; Masanao Kyuuma; Toshikazu Takeshita; Richard A Flavell; Roger J Davis
Journal:  Genes Dev       Date:  2003-07-31       Impact factor: 11.361

9.  Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653.

Authors:  Masataka Nishikawa; Akira Myoui; Tetsuya Tomita; Koichiro Takahi; Akihide Nampei; Hideki Yoshikawa
Journal:  Arthritis Rheum       Date:  2003-09

10.  Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization.

Authors:  Niina Reunanen; Song-Ping Li; Matti Ahonen; Marco Foschi; Jiahuai Han; Veli-Matti Kähäri
Journal:  J Biol Chem       Date:  2002-06-11       Impact factor: 5.157

View more
  22 in total

1.  Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice.

Authors:  Deepa Hammaker; Katharyn Topolewski; Meghan Edgar; Toshio Yoshizawa; Akihisa Fukushima; David L Boyle; Esther Cory Burak; Robert L Sah; Gary S Firestein
Journal:  Arthritis Rheum       Date:  2012-03

Review 2.  Cellular targeting in autoimmunity.

Authors:  Jennifer L Rogers; Donald S Serafin; Roman G Timoshchenko; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

3.  Overexpression of Ste20-related proline/alanine-rich kinase exacerbates experimental colitis in mice.

Authors:  Yutao Yan; Hamed Laroui; Sarah A Ingersoll; Saravanan Ayyadurai; Moiz Charania; Stephen Yang; Guillaume Dalmasso; Tracy S Obertone; Hang Nguyen; Shanthi V Sitaraman; Didier Merlin
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

Review 4.  Non-'classical' MEKs: A review of MEK3-7 inhibitors.

Authors:  Ada J Kwong; Karl A Scheidt
Journal:  Bioorg Med Chem Lett       Date:  2020-04-23       Impact factor: 2.823

Review 5.  "Go upstream, young man": lessons learned from the p38 saga.

Authors:  D Hammaker; G S Firestein
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

Review 6.  Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors.

Authors:  Nunzio Bottini; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

7.  Identification of potential peripheral blood diagnostic biomarkers for patients with juvenile idiopathic arthritis by bioinformatics analysis.

Authors:  Zhi-Qiang Tu; Hai-Yan Xue; Wei Chen; Lan-Fang Cao; Wei-Qi Zhang
Journal:  Rheumatol Int       Date:  2016-11-19       Impact factor: 2.631

8.  Correlation between cold and hot pattern in traditional Chinese medicine and gene expression profiles in rheumatoid arthritis.

Authors:  Miao Jiang; Cheng Xiao; Gao Chen; Cheng Lu; Qinglin Zha; Xiaoping Yan; Weiping Kong; Shijie Xu; Dahong Ju; Pu Xu; Youwen Zou; Aiping Lu
Journal:  Front Med       Date:  2011-06-22       Impact factor: 4.592

Review 9.  Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.

Authors:  Beatrix Bartok; Gary S Firestein
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

Review 10.  Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes.

Authors:  Gyrid Nygaard; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2020-05-11       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.